Patents by Inventor Joseph A. Martial
Joseph A. Martial has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 9714269Abstract: The present invention relates to quality control methods using inorganic binding peptides, wherein inorganic entities are identified using inorganic-binding peptides specifically binding to the inorganic entity of interest. In particular, the invention includes a method for the identification of defects or inhomogeneities on a surface by detecting an inorganic entity of interest. It further includes a method for the isolation of powder particles comprising an inorganic entity of interest from a mixture of powder particles. In addition, the present invention relates to inorganic-binding peptides comprising the amino acid sequence MTWDPSLASPRS (SEQ ID NO: 31) and the amino acid sequence LNAAVPFTMAGS (SEQ ID NO: 32), respectively.Type: GrantFiled: July 6, 2009Date of Patent: July 25, 2017Assignees: UNIVERSITE DE LIEGE INTERFACE ENTERPRISES UNIVERSITE, ARCELORMITTAL INVESTIGACIÓN Y DESARROLLO, S.L., GESVAL S.A., SYMBIOSE BIOMATERIALS S.A.Inventors: Christelle Vreuls, Cécile Van De Weerdt, Catherine Archembeau, André Renard, Joseph Martial
-
Publication number: 20130035289Abstract: The present disclosure relates to a pharmaceutical composition for use in the preventive and/or therapeutic treatment of thrombosis-related diseases or conditions relating to high level of plasminogen activator inhibitor 1 (PAI-1) expression, which composition comprises: A) a fragment of a polypeptide or protein of prolactin (PRL)-growth hormone (GH)-placental lactogen (PL)-family and homologous derivatives thereof, which fragment comprises from 6 to 14 consecutive amino acid residues of the amino acid sequence having general formula (I); or B) a peptide or a recombinant protein comprising said peptide, wherein the peptide is from 6 to 50 amino acids in length and has the activity to inhibit PAI-1, said peptide comprising from 6 to 14 consecutive amino acid residues of the amino acid sequence of general formula (I); or C) a polynucleotide encoding said fragment of a polypeptide or protein of A) or said peptide or recombinant protein of B).Type: ApplicationFiled: February 16, 2011Publication date: February 7, 2013Applicant: UNIVERSITE DE LIEGEInventors: Ingrid Struman, Joseph Martial, Khalid Bajou, Salvino D'Amico
-
Publication number: 20130035245Abstract: The present invention relates to quality control methods using inorganic binding peptides, wherein inorganic entities are identified using inorganic-binding peptides specifically binding to the inorganic entity of interest. In particular, the invention includes a method for the identification of defects or inhomogeneities on a surface by detecting an inorganic entity of interest. It further includes a method for the isolation of powder particles comprising an inorganic entity of interest from a mixture of powder particles. In addition, the present invention relates to inorganic-binding peptides comprising the amino acid sequence MTWDPSLASPRS (SEQ ID NO: 31) and the amino acid sequence LNAAVPFTMAGS (SEQ ID NO: 32), respectively.Type: ApplicationFiled: July 6, 2009Publication date: February 7, 2013Applicants: ARCELORMITTAL LIEGE RESEARCH, UNIVERSITE DE LIEGE INTERFACE ENTREPRISES UNIVERSITEInventors: Christelle Vreuls, Cécile Van De Weerdt, Catherine Archembeau, André Renard, Joseph Martial
-
Patent number: 7655626Abstract: The present invention refers to a pharmaceutical composition comprising an isolated antiangiogenic peptide or a recombinant protein comprising the antiangiogenic peptide, wherein the peptide is between 11 and 40 amino acids in length and having antiangiogenic activity, the peptide comprising the amino acid sequence: X1-X2-X3-X4-X5-X6-X7-X8-X9-X10-X11-X12-X13-X14, wherein X1 is any amino acid residue compatible with forming a helix; X2 is an amino acid residue of: Leu, Ile, Val; X3 is an amino acid residue of: Arg, Lys, His, Ser, Thr; X4 is an amino acid residue of: Ile, Leu, Val; X5 is any amino acid residue compatible with forming a helix; X6 is an amino acid residue of: Leu, Ile, Val; X7 is an amino acid residue of: Leu, Ile, Val, Ser, Thr; X8 is any amino acid residue compatible with forming a helix; X9 is any amino acid residue compatible with forming a helix; X10 is an amino acid residue of: Gln, Glu, Asp, Arg, His, Lys, Asn; X11 is an amino acid residue of: Ser, Thr; X12 is an amino acid residue of: TrpType: GrantFiled: August 11, 2005Date of Patent: February 2, 2010Assignees: Universite de Liege, Faculte Universitaire des Sciences Agronomiques de GemblouxInventors: Joseph Martial, Ingrid Struman, Ngoc-Quynh-Nhu Nguyen, Robert Brasseur, Laurence Lins
-
Publication number: 20080096795Abstract: The current invention concerns novel antiangiogenic peptides which correspond to about 10 to about 150 consecutive amino acids of N-terminal sequences of human growth hormone, human placental lactogen, human growth hormone variant hGH-V, and prolactin, and their use in inhibiting angiogenesis and in the diagnosis of diseases of human pregnancy involving abnormalities of placental vascularization.Type: ApplicationFiled: October 19, 2007Publication date: April 24, 2008Applicant: THE REGENTS OF THE UNIVERSITY OF CALIFORNIAInventors: Richard Weiner, Joseph Martial, Ingrid Struman, Robert Taylor, Frauke Bentzien
-
Publication number: 20080090750Abstract: The current invention concerns novel antiangiogenic peptides which correspond to about 10 to about 150 consecutive amino acids of N-terminal sequences of human growth hormone, human placental lactogen, human growth hormone variant hGH-V, and prolactin, and their use in inhibiting angiogenesis and in the diagnosis of diseases of human pregnancy involving abnormalities of placental vascularization.Type: ApplicationFiled: October 19, 2007Publication date: April 17, 2008Applicant: THE REGENTS OF THE UNIVERSITY OF CALIFORNIAInventors: Richard Weiner, Joseph Martial, Ingrid Struman, Robert Taylor, Frauke Bentzien
-
Publication number: 20080039384Abstract: The present invention refers to a pharmaceutical composition comprising an isolated antiangiogenic peptide or a recombinant protein comprising the antiangiogenic peptide, wherein the peptide is between 11 and 40 amino acids in length and having antiangiogenic activity, the peptide comprising the amino acid sequence: X1-X2-X3-X4-X5-X6-X7-X8-X9-X10-X11-X12-X13-X14, wherein X1 is any amino acid residue compatible with forming a helix; X2 is an amino acid residue of: Leu, Ile, Val; X3 is an amino acid residue of: Arg, Lys, His, Ser, Thr; X4 is an amino acid residue of: Ile, Leu, Val; X5 is any amino acid residue compatible with forming a helix; X6 is an amino acid residue of: Leu, Ile, Val; X7 is an amino acid residue of: Leu, Ile, Val, Ser, Thr; X8 is any amino acid residue compatible with forming a helix; X9 is any amino acid residue compatible with forming a helix; X10 is an amino acid residue of: Gln, Glu, Asp, Arg, His, Lys, Asn; X11 is an amino acid residue of: Ser, Thr; X12 is an amino acid residue of: TrpType: ApplicationFiled: August 11, 2005Publication date: February 14, 2008Applicant: UNIVERSITE DE LIEGEInventors: Joseph Martial, Ingrid Struman, Ngoc-Quynh-Nhu Nguyen, Robert Brasseur, Laurence Lins
-
Patent number: 7300920Abstract: The current invention provides novel antiangiogenic peptides which correspond to about 133 consecutive amino acids of the N-terminal sequence of growth hormone.Type: GrantFiled: November 14, 2003Date of Patent: November 27, 2007Assignee: The Regents of the University of CaliforniaInventors: Richard I. Weiner, Joseph A. Martial, Ingrid Struman, Robert Taylor, Frauke Bentzien
-
Publication number: 20040077054Abstract: The current invention concerns novel antiangiogenic peptides which correspond to about 10 to about 150 consecutive amino acids of N-terminal sequences of human growth hormone, human placental lactogen, human growth hormone variant hGH-V, and prolactin, and their use in inhibiting angiogenesis and in the diagnosis of diseases of human pregnancy involving abnormalities of placental vascularization.Type: ApplicationFiled: November 14, 2003Publication date: April 22, 2004Applicant: The Regents of the University of CaliforniaInventors: Richard I. Weiner, Joseph A. Martial, Ingrid Struman, Robert Taylor, Frauke Bentzien
-
Publication number: 20030186382Abstract: The current invention concerns novel antiangiogenic peptides which correspond to about 10 to about 150 consecutive amino acids of N-terminal sequences of human growth hormone, human placental lactogen, human growth hormone variant hGH-V, and prolactin, and their use in inhibiting angiogenesis and in the diagnosis of diseases of human pregnancy involving abnormalities of placental vascularization.Type: ApplicationFiled: March 27, 2001Publication date: October 2, 2003Inventors: Richard I. Weiner, Joseph A. Martial, Ingrid Struman, Robert Taylor, Frauke Bentzien
-
Patent number: 6322793Abstract: An attenuated, avirulent recombinant vaccine providing challenged protection against channel catfish virus comprises deletion of gene 50. Gene 50 encodes a secreted glycoprotein. Removal of gene 50, or replacement of gene 50 with foreign genetic material, provides a vaccine with which induces virus specific immunity against CCV disease.Type: GrantFiled: June 16, 1999Date of Patent: November 27, 2001Assignee: Mississippi State UniversityInventors: Nathalie Vanderheijden, Joseph A. Martial, Larry A. Hanson
-
Patent number: 5206163Abstract: The nucleotide sequence of the genome for bovine diarrhea virus (BDV) is disclosed. The sequence permits design and construction of vaccines effective against BDV.Type: GrantFiled: July 6, 1990Date of Patent: April 27, 1993Assignee: Chiron CorporationInventors: Andre Renard, Dino Dina, Joseph Martial
-
Patent number: 4725549Abstract: A DNA which comprises a deoxynucleotide sequence coding for prolactin, particularly human prolactin, is described. A transfer vector and an expression vector containing this DNA and microorganisms transformed by these vectors are also described. A method for preparing a reverse transcript (cDNA) from a messenger RNA is also disclosed herein.The invention described herein was made in the course of, or under, a grant from the National Institutes of Health.Type: GrantFiled: March 23, 1984Date of Patent: February 16, 1988Assignee: The Regents of the University of CaliforniaInventors: Nancy E. Cooke, John D. Baxter, Joseph A. Martial
-
Patent number: 4675297Abstract: A DNA sequence encoding bovine prolactin and optionally including condons for the preceding 10 amino acids is used to construct expression systems to obtain recombinant production of these proteins.Type: GrantFiled: September 14, 1983Date of Patent: June 23, 1987Assignee: The Regents of the University of CaliforniaInventors: John D. Baxter, Walter L. Miller, Joseph A. Martial